Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Faron Pharmaceuticals Oy ( (GB:FARN) ) has issued an update.
Faron Pharmaceuticals Ltd has appointed Jurriaan Dekkers as its new Chief Financial Officer, effective December 1, 2025, to support the company’s next growth phase. Dekkers, with over 20 years of experience in biopharma and healthcare, is expected to play a crucial role in advancing Faron’s lead asset, bexmarilimab, as it enters a registrational study, following the retirement of the current CFO, Yrjö Wichmann.
More about Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd is a global, clinical-stage biopharmaceutical company focused on developing novel immunotherapies to tackle cancers. Its lead asset, bexmarilimab, is an innovative macrophage-guiding immunotherapy being explored in various oncology settings, aiming to harness the immune system’s power to combat cancer.
See more data about FARN stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “…Overlook a Lack of Earnings Power”: UBS Analysts Target Intel Stock (NASDAQ:INTC), Stock Gains
- “…Significantly Extend the Reach and Lethality of our Fleet”: Boeing Stock (NYSE:BA) Slips Despite Successful MQ-25A Test
- “Direct Result of Your Feedback….” Microsoft Stock (NASDAQ:MSFT) Slips as The Option to Skip Updates Emerges